Be a Smart Investor
Thursday, March 17, 2016
Bio Blast Pharma (ORPN) Surged On Positive Phase 2 Study News
Bio Blast Pharma Ltd. (ORPN) announced positive results from its HOPEMD Phase 2 clinical study in patients with oculopharyngeal muscular dystrophy.
from RTT - Before the Bell http://ift.tt/1PdzM2X
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment